Latest Breaking News On - Nephrogenic diabetes insipidus - Page 1 : comparemela.com

Perceptive Advisors closes $515M fund to fuel more early-stage biotech startups Perceptive Advisors closes $515M fund to fuel more early-stage biotech startups Perceptive Advisors has $515 million for its second fund investing in biotech startups. Portfolio Manager Chris Garabedian says Perceptive Xontogeny Ventures Fund II is looking to make Series A investments in early-stage companies with assets that can show a path to clinical testing. Shares0   When Chris Garabedian set out early last year to raise money for a second Perceptive Advisors fund focused on early-stage biotech startups, it took just a matter of months to draw interest from investors willing to commit more than $1 billion total. The fund could have closed with that much money, maybe more, said Garabedian, the portfolio manager. But it ended up with a little more than half of that, which he described as “the right size.”

University of pennsylvaniaUnited statesBen askewLandos biopharmaQuellis biosciencesChris garabedianFred calloriCatabasis pharmaceuticalsGilead sciencesNational institute of healthRosalind franklin universityDuke universityPerceptive advisorsPerceptive xontogeny venturesSarepta therapeuticsNephraegis therapeutics